Remedy Pharmaceuticals, Inc.


Remedy Pharmaceuticals is a clinical-stage pharmaceutical company based in New York, focused on developing and bringing lifesaving treatments to people affected by acute central nervous system (CNS) injuries and diseases. The company is advancing the development of CIRARA, a drug for severe stroke conditions such as large hemispheric infarction, with a strong pipeline of clinical trials and patents. Their mission is to improve outcomes for patients with devastating CNS injuries.

Industries

biotechnology
health-care
pharmaceutical

Nr. of Employees

small (1-50)

Remedy Pharmaceuticals, Inc.


Products

Intravenous glyburide formulation (clinical-stage therapeutic candidate)

A proprietary intravenous formulation of glyburide developed for treatment of large-territory acute ischemic stroke to reduce malignant cerebral edema and improve functional outcomes; evaluated in Phase 2 and Phase 3 randomized clinical trials.


Services

Clinical-stage drug development for acute CNS injuries

End-to-end clinical development activities for investigational therapies targeting acute central nervous system injuries, including trial design, execution, regulatory engagement, and data dissemination.

Expertise Areas

  • Clinical trial management
  • Acute stroke therapeutics development
  • Neurocritical care clinical research
  • Regulatory strategy and FDA interactions for CNS drugs
  • Show More (3)

Key Technologies

  • CT perfusion (CTP) imaging
  • MRI diffusion-weighted imaging
  • ASPECTS scoring
  • NIH Stroke Scale (NIHSS)
  • Show More (5)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.